GD2/CD70 Bi-specific CAR-T Cell Therapy
- Conditions
- Cancer Disease
- First Posted Date
- 2022-06-30
- Last Posted Date
- 2022-06-30
- Lead Sponsor
- Shenzhen Geno-Immune Medical Institute
- Target Recruit Count
- 30
- Registration Number
- NCT05438368
- Locations
- 🇨🇳
Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China
GD2/PSMA Bi-specific CAR-T Cell Therapy
- Conditions
- Solid Tumor
- First Posted Date
- 2022-06-29
- Last Posted Date
- 2022-06-29
- Lead Sponsor
- Shenzhen Geno-Immune Medical Institute
- Target Recruit Count
- 60
- Registration Number
- NCT05437315
- Locations
- 🇨🇳
Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China
CD19/79b Bi-specific CAR-T Cell Therapy
- Conditions
- B Cell Malignancies
- First Posted Date
- 2022-06-29
- Last Posted Date
- 2022-06-29
- Lead Sponsor
- Shenzhen Geno-Immune Medical Institute
- Target Recruit Count
- 60
- Registration Number
- NCT05436509
- Locations
- 🇨🇳
Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China
PSMA/CD70 Bi-specific CAR-T Cell Therapy
- Conditions
- Cancer Disease
- First Posted Date
- 2022-06-29
- Last Posted Date
- 2022-06-29
- Lead Sponsor
- Shenzhen Geno-Immune Medical Institute
- Target Recruit Count
- 60
- Registration Number
- NCT05437341
- Locations
- 🇨🇳
Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China
GD2/CD56 Bi-specific CAR-T Cell Therapy
- Conditions
- Malignant Disease
- First Posted Date
- 2022-06-29
- Last Posted Date
- 2022-06-29
- Lead Sponsor
- Shenzhen Geno-Immune Medical Institute
- Target Recruit Count
- 60
- Registration Number
- NCT05437328
- Locations
- 🇨🇳
Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China
CD19/70 Bi-specific CAR-T Cell Therapy
- Conditions
- B Cell Malignancies
- First Posted Date
- 2022-06-29
- Last Posted Date
- 2022-06-29
- Lead Sponsor
- Shenzhen Geno-Immune Medical Institute
- Target Recruit Count
- 30
- Registration Number
- NCT05436496
- Locations
- 🇨🇳
Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China
CD19/22 Bi-specific CAR-T Cell Therapy
- Conditions
- B Cell Malignancies
- First Posted Date
- 2022-06-27
- Last Posted Date
- 2022-06-27
- Lead Sponsor
- Shenzhen Geno-Immune Medical Institute
- Target Recruit Count
- 60
- Registration Number
- NCT05432882
- Locations
- 🇨🇳
Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China
NGS-MRD Assessment of Combination Immunotherapies Targeting T-ALL
- Conditions
- T-Cell Acute Lymphoblastic Leukemia
- First Posted Date
- 2022-03-14
- Last Posted Date
- 2022-03-15
- Lead Sponsor
- Shenzhen Geno-Immune Medical Institute
- Target Recruit Count
- 10
- Registration Number
- NCT05277753
- Locations
- 🇨🇳
Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China
NGS-MRD Assessment of Combination Immunotherapies Targeting B-ALL
- Conditions
- B-Cell Acute Lymphoblastic Leukemia
- First Posted Date
- 2022-03-02
- Last Posted Date
- 2022-03-08
- Lead Sponsor
- Shenzhen Geno-Immune Medical Institute
- Target Recruit Count
- 10
- Registration Number
- NCT05262673
- Locations
- 🇨🇳
Shenzhen Geno-Immune Medical Institute, Shenzhen, Guangdong, China
4SCAR-T Therapy Targeting GD2, PSMA and CD276 for Treating Neuroblastoma
- Conditions
- Neuroblastoma
- First Posted Date
- 2020-11-19
- Last Posted Date
- 2020-11-19
- Lead Sponsor
- Shenzhen Geno-Immune Medical Institute
- Target Recruit Count
- 100
- Registration Number
- NCT04637503
- Locations
- 🇨🇳
Guangdong Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, China
🇨🇳Shenzhen Children's Hospital, Shenzhen, Guangdong, China
🇨🇳Shenzhen Geno-Immune Medical Institute, Shenzhen, Guangzhou, China